Ian Jenkins, CEO of Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The
Company”) met in an informal meeting with Canadian Prime Minister,
Justin Trudeau to discuss how Frelii’s artificial intelligence (AI)
technology could be beneficial in advancing the safe and more effective
use of medical cannabis products in Canada.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190415005618/en/
Frelii CEO, Ian Jenkins (Right) met Canada Prime Minister, Justin Trudeau (Left). Discussion included how AI and DNA analysis can advance the medical cannabis industry. (Photo: Business Wire)
“This was our first opportunity to meet with the prime minister,” said
Ian Jenkins, CEO of Frelii Inc. “Frelii has been working with regulatory
officials and physicians in Canada to prepare to deploy our AI
technology there. It is designed to enable medical professionals and
their patients to use cannabis products, such as CBD, more safely and
effectively than the current, trial-and-error approach.”
The use of marijuana for medical purposes has been legal in Canada since
2001. In 2018, the country became the first major world economy to
legalize recreational marijuana. Because of its national laws and
relaxed regulations, the country is better suited at this time for use
of this technology than other countries with more prohibitive laws.
“It is my opinion that Canada would be an ideal epicenter of initial
wide deployment of our technology,” Jenkins said. “The environment is
primed for expansion as the government was the first to deregulate the
whole CBD space. We will be able to grow in an environment where the
regulations support the expansion of a responsible approach for the safe
consumption of cannabis products. Mr. Trudeau said he was encouraged
that Frelii was going to deploy its technology there and opened the door
for introductions to the minister of innovation, science and economic
development, Navdeep Bains.”
Jenkins added that the Prime Minister welcomed the opportunity for
Frelii to look at Canada as a venue to expand into.
About Frelii Inc.
Frelii Inc. is a medical technology company that uses gene sequencing
and artificial intelligence to determine risk and lifestyle
modifications. Its technology analyzes the most comprehensive markers
(60,000,000+) on the market to date. Frelii’s technology generates
accurate and profoundly valuable insight into DNA. It opens
opportunities never before realized in health care, precision medicine,
insurance, corporate wellness as well as personal health and risk
identification. For more information, please visit www.frelii.com.
Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage
and developing U.S. and international companies. Companies are current
in their reporting and undergo an annual verification and management
certification process. Investors can find Real-Time quotes and market
information for the company on www.otcmarkets.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii
Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii
LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to
the business of the Company. All statements, other than statements of
historical fact included herein are “forward-looking statements”
including statements regarding: the continued growth of the e-commerce
segment and the ability of the Company to continue its expansion into
that segment; the ability of the Company to attract customers and
partners and generate revenues; the ability of the Company to
successfully execute its business plan; the business strategy, plans,
and objectives of the Company; and any other statements of
non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this news release. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a result
of a variety of factors, including those discussed in the Company’s
periodic reports that are filed with the Securities and Exchange
Commission and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company
does not assume any duty to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190415005618/en/